These results were further validated in vivo using xenograft mouse models, where manipulation of METTL3 expression affects tumor size and glucose uptake, highlighting the crucial role of the METTL3-IMP2 axis in CRC progression [16]. The gene discussed is IGF2BP2; the disease is neoplasm.